loading page

Gemtuzumab ozogamicin monotherapy is a well-tolerated palliative chemotherapy option in pediatric multiply relapsed acute myeloid leukemia: a multi-center case series and review of the literature
  • +1
  • Sarah Blain,
  • Noémie Payette,
  • Henrique Bittencourt,
  • Donna Johnston
Sarah Blain
University of Ottawa Faculty of Medicine

Corresponding Author:sarah.blain@umontreal.ca

Author Profile
Noémie Payette
Universite de Montreal
Author Profile
Henrique Bittencourt
Universite de Montreal
Author Profile
Donna Johnston
University of Ottawa Faculty of Medicine
Author Profile

Abstract

Gemtuzumab ozogamicin (GO) is an anti-CD33 antibody that is FDA approved in upfront acute myeloid leukemia (AML) for patients over 1 month-old, and for relapsed or refractory AML in patients over 2 years-old. GO is now integrated in upfront pediatric AML treatment, and often in CD33+ relapse treatment combined with intensive conventional chemotherapy. Although GO was initially tested as a monotherapeutic agent in relapsed or refractory AML ([1](#ref-0001) ,[2](#ref-0002)), there are few data in pediatric patients supporting this indication. In this review, we report 4 cases of multiply relapsed pediatric AML patients that were treated with GO monotherapy with palliative intent. Three out of 4 patients obtained a complete response with GO re-induction, either as monotherapy or paired with conventional chemotherapy. Three patients remained in remission respectively for 5, 17, and 9 months with GO continuation monotherapy. The literature was reviewed regarding the use of GO in pediatric AML relapse settings.